Brief counseling for reducing sexual risk and bacterial STIs among drug users-Results from project RESPECT

Drug and Alcohol Dependence

Volumn 106, Issue 1, 2010, Pages 7-15

  Semaan, Salaam ^a   Neumann, Mary Spink ^a   Hutchins, Kathleen ^a   D'Anna, Laura Hoyt ^b   Kamb, Mary L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Injection drug users; Project RESPECT; Risk reduction; Sexual risk behaviors; Sexually transmitted diseases; Substance use

Indexed keywords

COCAINE; DIAMORPHINE; HEPATITIS B CORE ANTIGEN;

ADULT; ARTICLE; BEHAVIOR CHANGE; CAUCASIAN; CHLAMYDIA; CHLAMYDIASIS; COCAINE DEPENDENCE; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; ECONOMIC ASPECT; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HISPANIC; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS; TRICHOMONIASIS;

ADULT; COCAINE-RELATED DISORDERS; COUNSELING; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK-TAKING; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; SYPHILIS;

BACTERIA (MICROORGANISMS); HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 2; TRICHOMONAS;

EID: 72149117132     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.07.015     Document Type: Article

References (76)

1. Ajzen I., and Fishbein M. Understanding Attitudes and Predicting Social Behavior (1980), Prentice-Hall, Inc., Englewood Cliffs, New Jersey
2. Amon J.J., Garfein R.S., Ahdieh-Grant L., Armstrong G.L., Ouellet L.J., Latka M.H., Vlahov D., Strathdee S.A., Hudson S.M., Kerndt P., Des Jarlais D., and Williams I.T. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin. Infect. Dis. 46 (2008) 1852-1858
3. Arasteh K., Des Jarlais D.C., and Perlis T.E. Alcohol and HIV sexual risk behaviors among injection drug users. Drug Alcohol Depend. 95 (2008) 54-61
4. Bachmann L.H., Lewis I., Allen R., Schwebke J.R., Leviton L.C., Siegal H.A., and Hook E.W. Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility. Am. J. Public Health 90 (2000) 1615-1618
5. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol. Rev. 84 (1977) 191-215
6. Becker M.H. The health belief model and personal health behavior. Health Educ. Monogr. 2 (1974) 324-473
7. Bolu O.O., Lindsey C., Kamb M.L., Kent C., Zenilman J., Douglas J.M., Malotte C.K., Rogers J., Peterman T.A., and for the Project RESPECT Study Group. Is HIV/sexually transmitted disease prevention counseling effective among vulnerable populations? A subset analysis of data collected for a randomized, controlled trial evaluating counseling efficacy (Project RESPECT). Sex. Transm. Dis. 31 (2004) 469-474
8. Booth R.E., Crowley T.J., and Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 42 (1996) 11-20
9. Borg L., Khuri E., Wells A., Melia E., Bergasa N.V., Ho Al., and Kreek M.J. Methadone maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction 94 (1999) 493
10. Boudreaux E.D., Wood K.B., Hehan D., Scarnici I., Taylor C.L., and Brantley P.J. Congruence of readiness to change, self-efficacy, and decisional balance for physical activity and dietary fat reduction. Am. J. Health Promot. 17 (2003) 329-336
11. Buffardi A.L., Thomas K.K., Holmes K.K., and Manhart L.E. Moving upstream: ecosocial and psychosocial correlates of sexually transmitted infections among young adults in the United States. Am. J. Public Health 98 (2008) 1128-1136
12. Buffington J., and Jones T.S. Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health. Public Health Rep. 122 (2007) 1-5
13. CDC AIDS Community Demonstration Projects Research Group. Community-level HIV intervention in 5 cities: final outcome data from the CDC AIDS Community Demonstration Projects. Am. J. Public Health 89 (1999) 336-345
14. Centers for Disease Control and Prevention. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings, and technical guidance on HIV counseling. MMWR CDC Rep. Recomm. 42 (1993) 157-158
15. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR CDC Rep. Recomm. 55 (2006) 1-17
16. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR CDC Rep. Recomm. 55 (2006) 1-94
17. Centers for Disease Control and Prevention. HIV prevalence estimates, United States, 2006. MMWR CDC Surveill. Summ. 57 (2008) 1073-1076
18. Centers for Disease Control and Prevention. Subpopulation estimates from the HIV incidence surveillance system, United States, 2006. MMWR CDC Surveill. Summ. 57 (2008) 985-989
19. Centers for Disease Control and Prevention, n.d. Diffusion of Effective Behavioral Interventions. Retrieved April 8, 2009, http://effectiveinterventions.org/. AED, Center on AIDS & Community Health.
20. Centers for Disease Control and Prevention, 2008c. Compendium of Evidence-Based HIV Prevention Interventions. Retrieved April 8, 2009, http://www.cdc.gov/hiv/topics/research/prs/evidence-based-interventions. Centers for Disease Control and Prevention, Atlanta, GA.
21. Corey L., Ashley R., and Valaciclovir HSV Transmission Study Group. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 11 (2004) 170A-174A
22. Des Jarlais D.C., and Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom. Med. 70 (2008) 606-611
23. Des Jarlais D., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D.D., McKnight C., Bramson H., Nemeth C., Torian L.V., and Friedman S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York city: a new stage in a very large HIV epidemic. AIDS 21 (2007) 231-235
24. Des Jarlais D.C., Diaz T., Perlis T., Vlahov D., Maslow C., Latka M., Rockwell R., Edwards V., Friedman S.R., Monterroso E., Williams I., and Garfein R.S. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am. J. Epidemiol. 157 (2003) 467-471
25. Des Jarlais D.C., Hagan H., Arasteh K., McKnight C., Perlman D., and Friedman S.R. Herpes simplex virus-2 and HIV among noninjecting drug users in New York city. Sex. Transm. Dis. 34 (2007) 923-927
26. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Beatrice S., Milliken J., Mildvan D., Yancovitz S., and Friedman S.R. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am. J. Public Health 95 (2005) 1439-1444
27. Des Jarlais D.C., and Semaan S. HIV prevention research: cumulative knowledge or accumulating studies?. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 30 (2002) S1-S7
28. Des Jarlais D.C., and Semaan S. Interventions to reduce the sexual risk behavior of injecting drug users. Int. J. Drug Policy 16 (2005) S58-S66
29. Des Jarlais D.C., and Semaan S. HIV and other sexually transmitted infections in injection drug users and crack cocaine smokers. In: Holmes K., Sparling P.F., Stamm W.E., Piot P., Wasserheit J.N., Corey L., Cohen M.S., and Watts D.H. (Eds). Sexually Transmitted Diseases (2008), McGraw Hill, New York 237-255
30. Des Jarlais D.C., and Semaan S. HIV prevention and psychoactive drug use: a research agenda. J. Epidemiol. Community Health 63 (2009) 191-196
31. Fleming D.T., and Wasserheit J.N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 75 (1999) 3-17
32. Friedman S.R., Kottiri B.J., Neaigus A., Curtis R., Vermund V.H., and Des Jarlais D.C. Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population group saturation. Am. J. Epidemiol. 152 10 (2000) 913-922
33. Gift T.L., and Marrazzo J. Cost effectiveness analysis. In: Aral S.O., Douglas J.M., and Lipshutz J.A. (Eds). Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases (2007), Springer, New York 482-499
34. Gottlieb S.L., Douglas J.M., Foster M., Schmid D.S., Newman D.R., Baron A.E., Bolan G., Iatesta M., Malotte C.K., Zenilman J., Fishbein M., Peterman T.A., Kamb M.L., and Project RESPECT Study Group. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk reduction counseling. J. Infect. Dis. 190 (2004) 1059-1067
35. Gyarmathy V.A., and Neaigus A. The relationship of sexual dyad and personal network characteristics and individual attributes to unprotected sex among young injecting drug users. AIDS Behav. (2007) 10.1007/s10461-007-9285-9
36. Harris R.M., Bausell R.B., Scott D.E., Hetherington S.E., and Kavanagh K.H. An intervention for changing high-risk HIV behaviors of African American drug-dependent women. Res. Nurs. Health 21 (1998) 239-250
37. Hennessy R.R., Weisfuse I.B., and Schlanger K. Does integrating viral hepatitis services into a public STD clinic attract injection drug users for care?. Public Health Rep. 122 (2007) 31-35
38. Kamb M.L., Dillon B.A., Fishbein M., Willis K.L., and Project RESPECT Study Group. Quality assessment of HIV prevention counseling in a multi-center randomized controlled trial. Public Health Rep. 111 (1996) 99-107
39. Kamb M.L., Fishbein M., Douglas Jr. J.M., Rhodes F., Rogers J., Bolan G., Zenilman J., Hoxworth T., Mallote K., Iatesta M., Kent C., Lentz A., Graziano S., Byers R.H., Peterman T.A., and Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized control trial. JAMA 280 (1998) 1161-1167
40. Kegeles S.M., Rebchook G.M., Hays R.B., Terry M.A., O'Donnell L., Leonard N.R., Kelly J.A., and Neumann M.S. From science to application: the development of an intervention package. AIDS Educ. Prev. 12 (2000) 62-74
41. Kral A.H., Bluthenthal R.N., Lorvick J., Gee L., Bacchetti P., and Edlin B.R. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 357 (2001) 1397-1401
42. Kresina T.F., Hoffman K., Lubran R., and Clark H.W. Integrating hepatitis services into substance abuse treatment programs: new initiatives from SAMHSA. Public Health Rep. 122 (2008) 96-98
43. Latkin C.A., Mandell W., Vlahov D., Oziemkowska M., and Celentano D.D. The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: The SAFE Study. Am. J. Community Psychol. 24 (1996) 341-364
44. Lally M.A., Alvarez S., Macnevin R., Cenedella C., Dispigno M., Harwell J.I., Pugatch D., and Flanigan T.P. Acceptability of sexually transmitted infection screening among women in short-term substance abuse treatment. Sex. Transm. Dis. 29 (2002) 752-755
45. Latka M., Ahern J., Garfien R.S., Ouellet L., Kerndt P., Morse P., Farshy C.E., Des Jarlais D.C., and Vlahov D. Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. J Subst. Abuse 13 (2001) 73-88
46. Lin J.S., Whitlock E., O'Connor E., and Bauer V. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149 (2008) 497-508
47. Lopez-Zetina J., Ford W., Weber M., Barna S., Woerhle T., Kerndt P., and Monterroso E. Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-1996. Sex. Transm. Infect. 76 (2000) 462-469
48. Malta M., Strathdee S.A., Magnanini M.M.F., and Bastos F.I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 103 (2008) 1242-1257
49. McKleroy V.S., Galbraith J.S., Cummings B., Jones P., Harshbarger C., Collins C., Gelaude D., Carey J.W., and ADAPT team. Adapting evidence-based behavioral interventions for new settings and target populations. AIDS Educ. Prev. 18 (2006) 59-73
50. McLaughlin P. Viral hepatitis vaccination in an opioid treatment program: Hartford, Connecticut, 2002-2005. Public Health Rep. 122 (2007) 48-51
51. Mezzelani P., Venturini L., Turrina G., Lugoboni F., and Des Jarlais D.C. High compliance with a hepatitis B virus vaccination program among intravenous drug users. J. Infect. Dis. 163 (1991) 923
52. Miller M., Liao Y., Gomez A.M., Gaydos C.A., and D'Mellow D. Factors associated with the prevalence and incidence of trichomonas vaginalis infection among African American women in New York city who use drugs. J. Infect. Dis. 197 (2008) 503-509
53. Miller M., Liao Y., Wagner M., and Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex. Transm. Dis. 35 (2008) 696-702
54. Miller M., and Neaigus A. Networks, resources and risk among women who use drugs. Soc. Sci. Med. 52 (2001) 967-978
55. Neaigus A., Miller M., Friedman S.R., and Des Jarlais D.C. Sexual transmission risk among non-injecting heroin users infected with HIV or hepatitis C virus. J. Infect. Dis. 184 (2001) 359-363
56. Peterman T.A., Lin L.S., Newman D.R., Kamb M.L., Bolan G., Zenilman J., Douglas J.M., Rogers J., and Malotte C.K. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study: Project RESPECT. Sex. Transm. Dis. 27 (2000) 446-451
57. Plitt S.S., Garfein R.S., Gaydos C.A., Strathdee S.A., Sherman S.G., and Taha T.E. Prevalence and correlates of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex. Transm. Dis. 32 (2005) 446-453
58. Rhodes F., and Malotte C.K. HIV risk interventions for active drug users: experience and prospects. In: Oskamp S., and Thompson S.C. (Eds). Understanding and Preventing HIV Risk Behavior: Safer Sex and Drug Use (1996), Sage Publications, Thousand Oaks, CA
59. Samet J.H., Krupitsky E.M., Cheng D.M., Raj A., Egorova V.Y., Levenson S., Meli S., Bridden C., Verbitskaya E.V., Kamb M.L., and Zvartau E.E. Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (partnership to reduce the Epidemic via engagement in narcology treatment) randomized controlled trial. Addiction 103 (2008) 1474-1483
60. Scheinmann R., Hagan H., Lelutiu-Weinberger C., Stern R., Des Jarlais D.C., Flom P.L., and Strauss S. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 89 (2007) 1-12
61. Semaan S., Des Jarlais D.C., and Malow R. Behavior change and health-related interventions for heterosexual risk reduction among drug users. Subst. Use Misuse 41 (2006) 1-29
62. Semaan S., Des Jarlais D.C., and Malow R.M. Sexually transmitted diseases among illicit drug users in the United States: the need for interventions. In: Aral S.O., and Douglas J. (Eds). Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases (2007), Springer-SBM, New York 397-430
63. Semaan S., Des Jarlais D.C., Sogolow E., Johnson W., Hedges L., Ramirez G., Flores S.A., Norman L., Sweat M., and Needle R. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 30 (2002) S73-S93
64. Strathdee S., Galai N., Safaiean M., Celentano D.D., Vlahov D., Johnson L., and Nelson K.E. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch. Intern. Med. 161 (2001) 1281-1288
65. Subiadur J., Harris J., and Rietmeijer C. Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep. 122 (2007) 12-17
66. Taylor L.E. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin. Infect. Dis. 15 (2005) S355-S361
67. Thompson D.L., Douglas J.M., Foster M., Hagansee M.E., DiGuiseppi C., Baron A.E., Cameron J.E., Spencer T.C., Zenilman J., Malotte C.K., Bolan G., Kamb M.L., Peterman T.A., and Project RESPECT Study Group. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J. Infect. Dis. 190 (2004) 1563-1574
68. Tortu S., Neaigus A., McMahon J., and Hagen D. Hepatitis C among noninjecting drug users: a report. Subst. Use Misuse 36 (2001) 523-534
69. U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 149 (2008) 491-496
70. Van der Pol B. The most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin. Infect. Dis. 44 (2007) 23-25
71. Ward J.W., and Fenton K.A. CDC and progress toward integration of HIV, STD, and viral hepatitis prevention. Public Health Rep. 122 (2007) 99-104
72. Warner L., Klausner J.D., Rietmeijer C.A., Malotte C.K., O'Donnell L., Margolis A.D., Greenwood G.L., Richardson D., Vrungos S., O'Donnell C.R., Borkowf C.B., and Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med. 5 (2008) 919-927
73. Warner L., Newman D.R., Austin H.D., Kamb M.L., Douglas J.M., Malotte C.K., Zenilman J.M., Rogers J., Bolan G., Fishbein M., Kleinbaum D.G., Macaluso M., and Peterman T.A. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am. J. Epidemiol. 159 (2004) 242-251
74. Warner L., Newman D.R., Kamb M.L., Fishbein M., Douglas Jr. J.M., Zenilman J., D'Anna L., Bolan G., Rogers J., Peterman T., and Project RESPECT Study Group. Problems with condom use among patients attending sexually transmitted disease clinics: prevalence, predictors, and relation to incident gonorrhea and chlamydia. Am. J. Epidemiol. 167 (2008) 349
75. Wood E., Hogg R.S., Dias Lima V., Kerr T., Yip B., Marshall B.D.L., and Montaner J.S.G. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 300 (2008) 550-554
76. Zimet G.D., Mays R.M., and Fortenberry J.D. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex. Transm. Dis. 27 (2000) 49-52